Ascentage Pharma Group International (AAPG)vsAlnylam Pharmaceuticals Inc (ALNY)
AAPG
Ascentage Pharma Group International
$22.32
0.00%
HEALTHCARE · Cap: $1.79B
ALNY
Alnylam Pharmaceuticals Inc
$308.05
+0.45%
HEALTHCARE · Cap: $41.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 851% more annual revenue ($3.71B vs $390.60M). ALNY leads profitability with a 8.4% profit margin vs -296.8%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
AAPG
Avoid15
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$308.05
$292.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 79.7x book value
ROE of -159.7% — below average capital efficiency
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 51.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
AAPG has a balanced fundamental profile.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : AAPG
The primary concerns for AAPG are EPS Growth, Market Cap, Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 133.4x leaves little room for execution misses.
Key Dynamics to Monitor
AAPG profiles as a turnaround stock while ALNY is a hypergrowth play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.87 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 15/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?